Conference Proceedings

Interim analysis of phase 2 results for Cemiplimab, a human monoclonal antibody to programmed death-1 (PD-1), in patients with locally advanced cutaneous squamous cell carcinoma

MR Migden, C Berking, ALS Chang, TK Eigentler, A Hauschild, L Hernandez-Aya, N Khushalani, KD Lewis, F Meier, B Modi, D Rischin, D Schadendorf, CD Schmults, C Ulrich, J Booth, S Li, K Mohan, E Stankevich, I Lowy, MG Fury

JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | WILEY | Published : 2019